| Autor: |
Hatzenbuehler LA; a Baylor College of Medicine , Houston , Texas.; b Texas Children's Hospital , Houston , TX , USA., Starke JR; a Baylor College of Medicine , Houston , Texas.; b Texas Children's Hospital , Houston , TX , USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2018 Sep; Vol. 16 (9), pp. 695-708. Date of Electronic Publication: 2018 Sep 07. |
| DOI: |
10.1080/14787210.2018.1513324 |
| Abstrakt: |
Introduction: Identifying and treating children with tuberculosis (TB) infection in both low and high-TB burden settings will decrease the incidence of TB disease worldwide. Areas covered: This review covers each of the available TB infection treatment options for children based on effectiveness, safety, tolerability and treatment completion rates. Six to 9 months of daily administered isoniazid is no longer the treatment of choice for many children with TB infection. Shorter, rifamycin based, TB infection treatment regimens are effective, safe and easier for children to complete. Fluroquinolone-based regimens are recommended for the treatment of children infected by a source case with drug-resistant TB. Directly observed therapy (DOT) programs improve childhood TB infection treatment completion rates. Expert commentary: As shorter, rifamycin-based, TB infection treatment regimens offer superior treatment success rate in both adults and children; the widespread use of these regimens has huge potential to decrease the burden of TB disease worldwide. The implementation of these programs will involve improving patient access to the medications, decreasing their cost to the patient, and the use of novel electronic methods to document patient treatment completion. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
